PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
8 hedge funds and large institutions have $41.1M invested in PDL BioPharma, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
9% more capital invested
Capital invested by funds: $37.9M → $41.1M (+$3.29M)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$83K |
Top Sellers
PDLI Hedge Fund Activity: Q3 2021 in Review
8 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2021, worth a combined $41.1M — up 8.7% from $37.9M a quarter earlier.
Fund positioning in PDLI was balanced in Q3 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Tudor Investment Corp, opening a new position worth an estimated $83K.
- 8 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $41.1M of PDL BioPharma, Inc. stock for Q3 2021, up 8.7% quarter-over-quarter.
- 1 fund opened new PDL BioPharma, Inc. positions in Q3 2021 and 1 closed out, a net change of 0 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2021 was Tudor Investment Corp, an estimated $83K added.
Based on aggregated 13F filings for Q3 2021.